Quantitative Characterization of the Exposure–Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma

To inform the benefit–risk assessment of nivolumab in patients with advanced melanoma, analyses of efficacy and safety exposure–response (E–R) relationships were conducted with data from patients with advanced melanoma enrolled in two clinical studies (phase I and phase III) who received nivolumab 0...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, X, Feng, Y, Bajaj, G, Gupta, M, Agrawal, S, Yang, A, Park, J‐S, Lestini, B, Roy, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270290/
https://www.ncbi.nlm.nih.gov/pubmed/28019090
http://dx.doi.org/10.1002/psp4.12133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270290/
https://www.ncbi.nlm.nih.gov/pubmed/28019090
http://dx.doi.org/10.1002/psp4.12133

Ejemplares similares